FDA Agrees To Pivotal Protocol For Oxigene’s Vascular Disrupting Agent Zybrestat
This article was originally published in The Pink Sheet Daily
Executive Summary
Oxigene has begun enrollment in the Phase II/III trial to test combretastatin-A4 in the orphan setting of anaplastic thyroid cancer.